Saxon Interests Inc. Makes New $694,000 Investment in CRISPR Therapeutics AG $CRSP

Saxon Interests Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 14,596 shares of the company’s stock, valued at approximately $694,000.

Several other institutional investors and hedge funds have also modified their holdings of CRSP. GSK plc purchased a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $168,890,000. Orbis Allan Gray Ltd lifted its stake in shares of CRISPR Therapeutics by 76.9% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after purchasing an additional 1,201,600 shares during the period. State Street Corp boosted its holdings in shares of CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after purchasing an additional 859,334 shares during the last quarter. ARK Investment Management LLC boosted its holdings in shares of CRISPR Therapeutics by 7.5% during the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock worth $551,777,000 after purchasing an additional 735,084 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at $25,706,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the transaction, the insider owned 19,357 shares in the company, valued at approximately $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CRSP. UBS Group set a $80.00 target price on CRISPR Therapeutics in a research note on Friday, June 12th. Wall Street Zen cut CRISPR Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Citizens Jmp reaffirmed a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Monday. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a report on Wednesday, May 27th. Finally, Truist Financial raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $67.78.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $60.77 on Wednesday. The business’s fifty day moving average price is $53.16 and its 200 day moving average price is $53.13. CRISPR Therapeutics AG has a twelve month low of $44.12 and a twelve month high of $78.48. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $5.86 billion, a P/E ratio of -9.77 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -4.89 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.